EPIX

ESSA Pharma Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website essapharma.com
Employees(FY) 50
ISIN CA29668H7085

Performance

-2.44%

-8.05%

-75.31%

-65.67%

-75.76%

YTD

-73.77%

Profile

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Advanced Technical Analysis

Technical Analysis of EPIX 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 31 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EPIX

Stock Rank

Recent News & Updates

2024-12-16 18:17
ESSA Pharma: Fiscal Q4 Earnings Snapshot(Yahoo Finance)
2024-12-16 18:00
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024(Prnewswire)
2024-11-03 19:14
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials(Yahoo Finance)
2024-10-31 20:14
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment(Yahoo Finance)
2024-10-31 08:57
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer(Prnewswire)
2024-09-14 09:53
ESSA Pharma Inc. (EPIX): Wall Street Analysts Recommend This Canadian Stock Right Now(Insidermonkey)
2024-09-13 05:19
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress(Prnewswire)
2024-09-11 04:05
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference(Prnewswire)
2024-08-04 19:03
ESSA Pharma: Fiscal Q3 Earnings Snapshot(Yahoo Finance)
2024-08-04 19:00
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024(Prnewswire)
2024-07-08 04:05
ESSA Pharma to Present at the JonesHealthcare Seaside Summit(Prnewswire)
2024-05-29 20:00
ESSA Pharma to Present at the Jefferies Global Healthcare Conference(Prnewswire)
2024-05-19 19:36
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday(Investorplace)
2024-05-14 01:54
EPIX Stock Earnings: ESSA Pharma Misses EPS for Q2 2024(Investorplace)
2024-05-13 19:04
ESSA Pharma: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
2024-05-13 19:00
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024(Prnewswire)
2024-04-08 20:00
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference(Prnewswire)
2024-03-07 07:13
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS(Prnewswire)
2024-02-26 00:14
12 $10 Stocks That Will Triple(Yahoo Finance)
2024-02-13 15:35
ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results(Yahoo Finance)
2024-02-12 18:25
ESSA Pharma: Fiscal Q1 Earnings Snapshot(Yahoo Finance)
2024-02-12 18:00
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023(Yahoo Finance)
2024-02-07 20:47
ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares(GuruFocus.com)
2024-02-06 08:00
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference(PR Newswire)
2024-02-05 19:00
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference(Prnewswire)
2024-01-26 05:36
EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…(Zacks Small Cap Research)
2024-01-25 10:00
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium(CNW Group)
2024-01-22 07:16
ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains(Simply Wall St.)
2023-12-21 16:13
These Stocks under $10 Are Poised To Explode(Insider Monkey)
2023-12-20 08:23
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…(Zacks Small Cap Research)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.